St Louis, MONCT06774963Now EnrollingIRB Ready

Ovarian Cancer Clinical Trial in St Louis, MO

Access cutting-edge ovarian cancer treatment through this clinical trial at a research site in St Louis. Study-provided care at no cost to qualified participants.

Sponsored by NextCure, Inc.

Quick Self-Assessment

See if you qualify for this St Louis location

Preparing your pre-screening questions…

Expert Care in St Louis

Access ovarian cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related ovarian cancer treatment provided free

Apply for This St Louis Location

Check if you qualify for this ovarian cancer clinical trial in St Louis, MO

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to St Louis

    Convenient for MO residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit St Louis site if eligible
  4. 4Begin participation

About This Ovarian Cancer Study in St Louis

This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.

Sponsor: NextCure, Inc.

Who Can Participate

Inclusion Criteria

The participant provides written informed consent
≥ 18 years of age on day of signing informed consent.
Participant with histologically or cytologically confirmed diagnosis of advanced unresectable and/or metastatic solid tumors
A male participant must agree to use contraception and refrain from sperm donation or expecting to father a child
A female participant is eligible to participate if she is not pregnant, not breastfeeding, not a woman of childbearing potential
Have measurable disease per RECIST 1.1 as assessed by the local site investigator/radiology
Able to provide tumor tissue sample.
Willing to undergo fresh tumor biopsy at Screening and On-treatment if archival tissue not available
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
Life expectancy greater than or equal to 12 weeks as judged by the Investigator.
Have adequate organ function

Exclusion Criteria

A WOCBP who has a positive serum pregnancy test (within 72 hours) prior to treatment.
Has received prior investigational agents within 4 weeks prior to treatment.
Has received anti-cancer chemotherapy (Immunotherapy (non-antibody-based therapy), retinoid therapy, hormonal therapy within 2 weeks prior to treatment.
Has received antibody-based anti-cancer therapy within 4 weeks prior to treatment.
Has received targeted agents and small molecules within 2 weeks or 5 half-lives, whichever is longer.
Has received prior platinum-based chemotherapy and progressed within 4 weeks of initiating therapy (platinum-refractory disease)
Has received an ADC with MMAE payload.
Has received prior radiotherapy within 2 weeks of start of study treatment for focal radiation or within 4 weeks for wide-field radiotherapy
Has received G-CSF or GM-CSF within 7 days prior to start of study treatment.
Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention.
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug
Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
Has known active CNS metastases and/or carcinomatous meningitis
Has severe hypersensitivity (≥ Grade 3), known allergy or reaction LNCB74 or any of its excipients.
Has a history of (non-infectious) pneumonitis / interstitial lung disease that required steroids or has current pneumonitis / interstitial lung disease.
Has active ≥Grade 2 sensory or motor neuropathy.
Has active or chronic corneal disorders, other active ocular conditions requiring ongoing therapy or any clinically significant corneal disease.
Has an active infection requiring systemic therapy.
Any major surgery within 4 weeks of study drug administration.
Toxicity (except for alopecia) related to prior anti-cancer therapy and/or surgery, unless the toxicity is either resolved, returned to baseline or Grade 1, or deemed irreversible.
Prior organ or tissue allograft.
Uncontrolled or significant cardiovascular disease
Participants with serious or uncontrolled medical disorders.
Participants who are on total parenteral nutrition (TPN)
Participants with history of bowel obstruction within one month of screening
Participants with history of significant ascites requiring paracentesis within 2 weeks of screening
Has a known history of human immunodeficiency virus (HIV) infection with an acquired immune deficiency syndrome (AIDS)-defining opportunistic infection within the last year, or a current CD4 count \<350 cells/µl
Has known active Hepatitis B (defined as HBsAg reactive) or known active Hepatitis C virus (defined as HCV RNA \[qualitative\] is detected) infection
Has a history or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the participant's participation for the full duration of the study
Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in St Louis?

Yes, this clinical trial (NCT06774963) has an active research site in St Louis, MO that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Ovarian Cancer Treatment Options in St Louis, MO

If you're searching for ovarian cancer treatment options in St Louis, MO, this clinical trial (NCT06774963) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our St Louis research site is actively enrolling participants for this clinical trial. You'll receive care from experienced ovarian cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all ovarian cancer clinical trials near you to find additional studies recruiting in your area.

More Ovarian Cancer Trials in St Louis, MO

See all ovarian cancer clinical trials recruiting in St Louis — not just this study.

Browse Ovarian Cancer Trials in St Louis →

Browse More Trials by Condition

Ovarian Cancer TrialsAll Conditions →

Ready to Join in St Louis?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · St Louis, MO